Role of pharmacogenetics in variable response to drugs: focus on opioids

Bibliography

• Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA 1993;90(12):5391-3
   PubMed Web of Science ®Google Scholar
• Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002;12(1):3-9
   PubMedGoogle Scholar
• Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360(9340):1155-62
   PubMed Web of Science ®Google Scholar
• Sim S, Ingelman-Sundberg M, Daly A, Nebert DW. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature. Available at: URL: www.cypalleles.ki.se [Accessed October 16, 2007]
   Google Scholar
• Dayer P, Desmeules J, Leemann T, Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun 1988;152(1):411-16
   Google Scholar
• Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007;81(3):429-44
   PubMed Web of Science ®Google Scholar
• Desmeules J, Gascon MP, Dayer P, Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991;41(1):23-6
   PubMed Web of Science ®Google Scholar
• Mikus G, Bochner F, Eichelbaum M, Horak P, Somogyi AA, Spector S. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism. J Pharmacol Exp Ther 1994;268(2):546-51
   PubMed Web of Science ®Google Scholar
• Kirkwood LC, Nation RL, Somogyi AA. Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. Br J Clin Pharmacol 1997;44(6):549-55
   PubMed Web of Science ®Google Scholar
• Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004;32(4):447-54
   PubMed Web of Science ®Google Scholar
• Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 2004;57(3):287-97
   PubMed Web of Science ®Google Scholar
• Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther 1992;260(1):275-85
   PubMed Web of Science ®Google Scholar
• Subrahmanyam V, Renwick AB, Young PJ, et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 2001;29(8):1146-55
   PubMed Web of Science ®Google Scholar
• Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996;60(6):636-44
   PubMed Web of Science ®Google Scholar
• Stamer UM, Lehnen K, Bayerer B, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003;105:231-8
   PubMed Web of Science ®Google Scholar
• Wang G, Zhang H, He F, Fang X. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 2006;62(11):927-31
   PubMed Web of Science ®Google Scholar
• Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol 2004;60(8):575-81
   PubMed Web of Science ®Google Scholar
• Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos 2005;33(5):689-95
   PubMed Web of Science ®Google Scholar
• Ramirez J, Innocenti F, Flockhart DA, et al. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 2004;32(9):930-6
   PubMed Web of Science ®Google Scholar
• Jin M, Gock SB, Jannetto PJ, Jentzen JM, Wong SH. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol 2005;29(7):590-8
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Croquette-Krokkar M, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005;78(6):593-604
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Bock KW, Guillemette C, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005;15(10):677-85
   PubMed Web of Science ®Google Scholar
• Nagar S, Remmel RP. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 2006;25(11):1659-72
   PubMed Web of Science ®Google Scholar
• Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997;25(1):1-4
   PubMed Web of Science ®Google Scholar
• King C, Tang W, Ngui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001;61(1):49-53
   PubMed Web of Science ®Google Scholar
• Bhasker CR, McKinnon W, Lo AC, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000;10(8):679-85
   PubMedGoogle Scholar
• Hirota T, Ieiri I, Sano H, et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos 2003;31(5):677-80
   PubMed Web of Science ®Google Scholar
• Court MH, Krishnaswamy S, Duan SX, et al. Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 2003;31(9):1125-33
   PubMed Web of Science ®Google Scholar
• Thibaudeau J, Lepine J, Duguay Y, et al. Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 2006;66(1):125-33
   PubMed Web of Science ®Google Scholar
• Sawyer MB, Innocenti F, Cheng C, et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003;73(6):566-74
   PubMed Web of Science ®Google Scholar
• Holthe M, Klepstad P, Borchgrevink PC, et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 2002;58(5):353-6
   PubMed Web of Science ®Google Scholar
• Holthe M, Rakvag TN, Idle JR, et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 2003;3(1):17-26
   PubMed Web of Science ®Google Scholar
• Coulbault L, Beaussier M, Weickmans H, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 2006;79(4):316-24
   PubMed Web of Science ®Google Scholar
• Ross JR, Rutter D, Joel SP, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 2005;5(5):324-36
   PubMed Web of Science ®Google Scholar
• Burchell B, Soars M, Monaghan G, Cassidy A, Smith D, Ethell B. Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases. Toxicol Lett 2000;112-113:333-40
   PubMed Web of Science ®Google Scholar
• Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999;51(4):593-628
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Ann Rev Pharmacol Toxicol 1999;39:19-52
   PubMed Web of Science ®Google Scholar
• Zubieta JK, Heitzeg MM, Bueller JA, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003;299(5610):1240-3
   PubMed Web of Science ®Google Scholar
• Kim H, Neubert JK, Xu K, et al. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 2004;109(3):488-96
   PubMed Web of Science ®Google Scholar
• Rakvag TT, Klepstad P, Kvam TM, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005;116:73-8
   PubMed Web of Science ®Google Scholar
• Reyes-Gibby CC, Shete S, Bhat SV, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007;130:25-30
   PubMed Web of Science ®Google Scholar
• Oswald LM, McCaul M, Choi L, Yang X, Wand GS. Catechol-O-methyltransferase polymorphism alters hypothalamic-pituitary-adrenal axis responses to naloxone: a preliminary report. Biol Psychiatry 2004;55(1):102-5
   PubMed Web of Science ®Google Scholar
• Diatchenko L, Slade GD, Bhalang K, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005;14(1):135-43
   PubMed Web of Science ®Google Scholar
• Diatchenko L, Nackley AG, Bhalang K, et al. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 2006;125(3):216-24
   PubMed Web of Science ®Google Scholar
• Berthele A, Platzer S, Boecker H, et al. COMT Val108/158Met genotype affects the mu-opioid receptor system in the human brain: evidence from ligand-binding, G-protein activation and preproenkephalin mRNA expression. Neuroimage 2005;28(1):185-93
   PubMed Web of Science ®Google Scholar
• Goldman D, Oroszi G, O'Malley S, Anton R. COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms. J Stud Alcohol 2005;56-64, discussion 33
   Web of Science ®Google Scholar
• Ganapathy V, Miyauchi S. Transport systems for opioid peptides in mammalian tissues. AAPS J 2005;7(4):E852-6
   PubMed Web of Science ®Google Scholar
• Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007;7(3):154-79
   PubMed Web of Science ®Google Scholar
• Wandel C, Kim R, Wood M, Wood A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 2002;96(4):913-20
   PubMed Web of Science ®Google Scholar
• Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;234(1):4-33
   PubMed Web of Science ®Google Scholar
• Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006;112(2):457-73
   PubMed Web of Science ®Google Scholar
• Drewe J, Ball HA, Peng B, et al. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol 2000;50(3):237-46
   PubMed Web of Science ®Google Scholar
• Lotsch J, Skarke C, Oertel BG, et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 2006;79(1):72-89
   PubMed Web of Science ®Google Scholar
• Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006;80(6):682-90
   PubMed Web of Science ®Google Scholar
• Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 2007;81(4):539-46
   PubMed Web of Science ®Google Scholar
• Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Ann Rev Biochem 2002;71:537-92
   PubMed Web of Science ®Google Scholar
• Crowe A. The influence of P-glycoprotein on morphine transport in Caco-2 cells. Comparison with paclitaxel. Eur J Pharmacol 2002;440(1):7-16
   PubMed Web of Science ®Google Scholar
• Lang T, Hitzl M, Mornhinweg E, et al. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 2004;14(3):155-64
   PubMedGoogle Scholar
• Saito S, Iida A, Miura Y, et al. Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR. J Hum Genet 2002;47(4):147-71
   PubMed Web of Science ®Google Scholar
• Wang H, Hao B, Chen X, et al. Linkage disequilibrium and haplotype architecture for two ABC transporter genes (ABCC1 and ABCG2) in Chinese population: implications for pharmacogenomic association studies. Ann Hum Genet 2004;68:563-73
   PubMed Web of Science ®Google Scholar
• Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood–brain barrier. J Pharmacol Exp Ther 2000;294(1):73-9
   PubMed Web of Science ®Google Scholar
• Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001;276(38):35669-75
   PubMed Web of Science ®Google Scholar
• Lee W, Glaeser H, Roberts RL, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 2005;280(10):9610-17
   PubMed Web of Science ®Google Scholar
• Mogil JS, Ritchie J, Strasburg K, et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet 2005;42(7):583-7
   PubMed Web of Science ®Google Scholar
• Henderson G, McKnight AT. The orphan opioid receptor and its endogenous ligand – nociceptin/orphanin FQ. Trends Pharmacol Sci 1997;18(8):293-300
   PubMed Web of Science ®Google Scholar
• Lotsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 2005;11(2):82-9
   PubMed Web of Science ®Google Scholar
• Bond C, LaForge KS, Melia D, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998;95(16):9608-13
   PubMed Web of Science ®Google Scholar
• Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 2001;276(5):3130-7
   PubMed Web of Science ®Google Scholar
• Beyer A, Koch T, Schroder H, Schulz S, Hollt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 2004;89(3):553-60
   PubMed Web of Science ®Google Scholar
• Skarke C, Darimont J, Schmidt H, Geisslinger G, Lotsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003;73(1):107-21
   PubMed Web of Science ®Google Scholar
• Romberg RR, Olofsen E, Taschner PE, et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 2005;102(3):522-30
   PubMed Web of Science ®Google Scholar
• Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 2006;16(9):625-36
   PubMed Web of Science ®Google Scholar
• Klepstad P, Rakvag TT, Holthe M, et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004;48(10):1232-9
   PubMed Web of Science ®Google Scholar
• Lotsch J, Zimmermann M, Darimont J, et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology 2002;97(4):814-9
   PubMed Web of Science ®Google Scholar
• Wand GS, McCaul M, Reynolds J, et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 2002;26(1):106-14
   PubMed Web of Science ®Google Scholar
• Oslin DW, Berrettini W, Pettinati H, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003;28(8):1546-52
   PubMed Web of Science ®Google Scholar
• Wang D, Quillan JM, Winans K, Lucas JL, Sadee W. Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem 2001;276(37):34624-30
   PubMed Web of Science ®Google Scholar
• Koch T, Kroslak T, Mayer P, et al. Allelic variation S268P of the human mu-opioid receptor affects both desensitization and G protein coupling. Mol Pharmacol 2000;58(2):328-34
   PubMed Web of Science ®Google Scholar
• Yuferov V, Fussell D, Nielsen DA, et al. Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenetics 2004;14(12):793-804
   PubMedGoogle Scholar
• Zhang H, Kranzler HR, Yang BZ, Luo X, Gelernter J. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry; 2007
   Google Scholar
• Mayer P, Rochlitz H, Rommelspacher H, et al. Association between a delta opioid receptor gene polymorphism and heroin dependence in man. Neuroreport 1997;8(11):2547-50
   PubMed Web of Science ®Google Scholar
• Franke P, Nothen MM, Neidt H, et al. Human delta-opioid receptor gene and susceptibility to heroin and alcohol dependence. Am J Med Genet 1999;88(5):462-4
   PubMed Web of Science ®Google Scholar
• Mayer P, Hollt V. Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics 2006;16(1):1-7
   PubMed Web of Science ®Google Scholar
• Szeto CY, Tang NL, Lee DT, Stadlin A. Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts. Neuroreport 2001;12(6):1103-6
   PubMed Web of Science ®Google Scholar
• Gerra G, Leonardi C, D'Amore A, et al. Human kappa opioid receptor gene (OPRK1) polymorphism is associated with opiate addiction. Am J Med Genet B Neuropsychiatr Genet 2007;144(6):771-5
   Web of Science ®Google Scholar
• Gelernter J, Gueorguieva R, Zhang H, et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 2007;31(4):555-63
   PubMed Web of Science ®Google Scholar
• Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006;368(9536):704
   PubMed Web of Science ®Google Scholar
• Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007;17(2):93-101
   PubMed Web of Science ®Google Scholar
• Ferrante FM. Principles of opioid pharmacotherapy: practical implications of basic mechanisms. J Pain Symptom Manage 1996;11(5):265-73
   PubMed Web of Science ®Google Scholar
• Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part I. Psychosomatics 2003;44(2):167-71
   PubMed Web of Science ®Google Scholar
• Klepstad P, Dale O, Skorpen F, Borchgrevink PC, Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 2005;49(7):902-8
   PubMed Web of Science ®Google Scholar
• Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II. Psychosomatics 2003;44(6):515-20
   PubMed Web of Science ®Google Scholar
• Prommer E. Oxymorphone: a review. Support Care Cancer 2006;14(2):109-15
   PubMed Web of Science ®Google Scholar
• Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone – metabolism, pharmacokinetics and interactions. Pharmacol Res 2004;50(6):551-9
   PubMed Web of Science ®Google Scholar
• Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 1996;82(1):167-72
   PubMed Web of Science ®Google Scholar
• Battershill AJ, Keating GM. Remifentanil: a review of its analgesic and sedative use in the intensive care unit. Drugs 2006;66(3):365-85
   PubMed Web of Science ®Google Scholar
• Raffa RB. A novel approach to the pharmacology of analgesics. Am J Med 1996;101(1A):40S-46S
   PubMedGoogle Scholar
• DeHaven-Hudkins DL, Burgos LC, Daubert JD, et al. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther 1999;289(1):494-502
   PubMed Web of Science ®Google Scholar
• Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998;26(1):73-7
   PubMed Web of Science ®Google Scholar
• King CD, Green MD, Coffman BL, et al. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch Biochem Biophys 1996;332(1):92-100
   PubMed Web of Science ®Google Scholar
• Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43(13):879-923
   PubMed Web of Science ®Google Scholar
• Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 2003;3(3):136-58
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Roots I, Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today 2001;6(16):835-9
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Oh JM, Sauna ZE, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315(5811):525-8
   PubMed Web of Science ®Google Scholar
• Lotsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004;43(14):983-1013
   PubMed Web of Science ®Google Scholar
• Lotsch J, Geisslinger G. Current evidence for a genetic modulation of the response to analgesics. Pain 2006;121:1-5
   PubMed Web of Science ®Google Scholar
• Lotsch J, Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J 2006;6(3):200-10
   PubMed Web of Science ®Google Scholar
• Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006;105(2):334-7
   PubMed Web of Science ®Google Scholar
• Chou WY, Yang LC, Ko JY, et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006;50(7):787-92
   PubMed Web of Science ®Google Scholar
• McGeary JE, Monti PM, Tidey J, et al. Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res 2006;30(8):1288-96
   PubMed Web of Science ®Google Scholar
• NCBI SNP database. Available at: URL: www.ncbi.nlm.nih.gov/sites/entrez [Accessed October 15, 2007]
   Google Scholar